Clinical trials: Treatment Refusal
Vaccine Hesitancy
The Impact of Community and Patient Engagement Practices on Vaccine Confidence in the United States
The primary objective of this study is to demonstrate an empirical relationship between community- engagement practices, and between patient-centric clinical trial design, execution and communication practices, and vaccine…
- Trial name
- NCT06374134
- Testing
- Community Engagement Practice, Patient-Centric Protocol Element
- Volunteers
- 30 people
- Sponsor
- Tufts University
Child Psychiatry, Adolescent
Cognitive and Behavioral Therapy in School Refusal
Anxious school refusal (ASR) is a common disorder which concerns more and more adolescents who are at worse completely absent from school.
- Conditions
- Child Psychiatry, Adolescent, Anxious School Refusal, Cognitive Behavioral Therapy
- Trial name
- RSA-Coll (NCT04559633)
- Testing
- cognitive and behavioral therapy (CBT)
- Where
- France
- Volunteers
- 66 people
- Sponsor
- University Hospital, Montpellier
Vaccine Refusal
Assessing Knowledge, Beliefs and Attitudes Toward HPV Vaccination Among Parents in North West, Cameroon
The aim of this study is to assess knowledge, beliefs and attitudes of parents to young girls aged 9 to 14 years about HPV vaccines within some rural communities in the North West Region of Cameroon served by three hospitals in…
- Trial name
- NCT05325138
- Testing
- Interview
- Where
- Cameroon
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- McMaster University
Carcinoma, Non-Small-Cell Lung
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC SBRT in patients with unresected clinical Stage I/II…
- Trial name
- PACIFIC-4 (NCT03833154)
- Testing
- Durvalumab, (Osimertinib cohort, single-arm, open-label separate cohort)
- Where
- 209 sites in United States, Australia and 18 more
- Volunteers
- 724 people
- Sponsor
- AstraZeneca